Paper33859356
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.
Bonaventura J and 13 others. Mol Psychiatry, 2021. Cited by 225 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Papers, record 33859356. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33859356
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Depressive Disorder, Treatment-Resistant | Major topic |
| Ketamine | Major topic |
| Animals | |
| Antidepressive Agents | |
| Depression | |
| Mice | |
| Rats | |
| Stereoisomerism |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| ZIA DA000069 | Intramural NIH HHS | United States | ZIADA000069 | PubMed and NIH | NIH RePORTER |
| ZIA DA000434 | Intramural NIH HHS | United States | ZIADA000434 | PubMed and NIH | NIH RePORTER |
| ZIA MH002927 | Intramural NIH HHS | United States | ZIAMH002927 | PubMed | NIH RePORTER |
| ZIA NS002263 | Intramural NIH HHS | United States | ZIANS002263 | PubMed and NIH | NIH RePORTER |
| ZIAMH002857 | NIH | NIH RePORTER | |||
| ZIATR000042 | NIH | NIH RePORTER |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 34,006,965 | Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al. | https://conductscience.org/library/papers/34006965 | PubMed |
| Comment in | 35,177,823 | Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al. | https://conductscience.org/library/papers/35177823 | PubMed |
References68
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10,686,270 | Antidepressant effects of ketamine in depressed patients. | Biol Psychiatry | 2000 | https://conductscience.org/library/papers/10686270 | PubMed |
| 2 | 20,679,587 | A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. | Arch Gen Psychiatry | 2010 | https://conductscience.org/library/papers/20679587 | PubMed |
| 3 | 16,894,061 | A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. | Arch Gen Psychiatry | 2006 | https://conductscience.org/library/papers/16894061 | PubMed |
| 4 | 22,297,150 | Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. | Biol Psychiatry | 2012 | https://conductscience.org/library/papers/22297150 | PubMed |
| 5 | 27,056,608 | A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. | Am J Psychiatry | 2016 | https://conductscience.org/library/papers/27056608 | PubMed |
| 6 | 23,982,301 | Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. | Am J Psychiatry | 2013 | https://conductscience.org/library/papers/23982301 | PubMed |
| 7 | 19,897,179 | Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. | Biol Psychiatry | 2010 | https://conductscience.org/library/papers/19897179 | PubMed |
| 8 | 27,878,517 | Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant. | Neurosci Bull | 2016 | https://conductscience.org/library/papers/27878517 | PubMed |
| 9 | 23,882,190 | Brain damages in ketamine addicts as revealed by magnetic resonance imaging. | Front Neuroanat | 2013 | https://conductscience.org/library/papers/23882190 | PubMed |
| 10 | 31,109,197 | A Word to the Wise About Intranasal Esketamine. | Am J Psychiatry | 2019 | https://conductscience.org/library/papers/31109197 | PubMed |
| 11 | 26,327,690 | R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. | Transl Psychiatry | 2015 | https://conductscience.org/library/papers/26327690 | PubMed |
| 12 | 29,945,898 | Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. | Pharmacol Rev | 2018 | https://conductscience.org/library/papers/29945898 | PubMed |
| 13 | 27,807,158 | Ketamine: NMDA Receptors and Beyond. | J Neurosci | 2016 | https://conductscience.org/library/papers/27807158 | PubMed |
| 14 | 21,692,801 | Potentiation of μ-opioid receptor-mediated signaling by ketamine. | J Neurochem | 2011 | https://conductscience.org/library/papers/21692801 | PubMed |
| 15 | 20,358,363 | Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. | Psychopharmacology (Berl) | 2010 | https://conductscience.org/library/papers/20358363 | PubMed |
| 16 | 6,086,884 | A novel phencyclidine analog interacts selectively with mu opioid receptors. | J Pharmacol Exp Ther | 1984 | https://conductscience.org/library/papers/6086884 | PubMed |
| 17 | 8,098,066 | Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-binding sites. | J Med Chem | 1993 | https://conductscience.org/library/papers/8098066 | PubMed |
| 18 | 2,544,905 | Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs. | Pharmacol Biochem Behav | 1989 | https://conductscience.org/library/papers/2544905 | PubMed |
| 19 | 15,852,061 | Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. | Mol Psychiatry | 2005 | https://conductscience.org/library/papers/15852061 | PubMed |
| 20 | 21,069,515 | Ketamine self-administration in the rat: evidence for a critical role of setting. | Psychopharmacology (Berl) | 2011 | https://conductscience.org/library/papers/21069515 | PubMed |
Cited by139
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 225 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,985,291 | Integrating multi-receptor and neuron-glia mechanisms of ketamine's antidepressant action: a convergence framework for understanding efficacy. | Front Mol Neurosci | 2026 | https://conductscience.org/library/papers/42985291 | PubMed |
| 42,803,524 | Multimodal predictors of response to intravenous ketamine in treatment-resistant depression: toward personalized treatment in major depressive and bipolar disorders. | CNS Spectr | 2026 | https://conductscience.org/library/papers/42803524 | PubMed |
| 42,706,419 | Is (S)-norketamine an active mediator of esketamine's antidepressant effects? | Mol Psychiatry | 2026 | https://conductscience.org/library/papers/42706419 | PubMed |
| 42,637,972 | Molecular snapshots confirm ketamine's opioid nature. | Nat Struct Mol Biol | 2026 | https://conductscience.org/library/papers/42637972 | PubMed |
| 42,494,734 | Treating addiction with an addictive drug: the ketamine paradox revisited. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42494734 | PubMed |
| 42,332,075 | Structural basis of opioid receptor activation by PCP and ketamine. | Nat Struct Mol Biol | 2026 | https://conductscience.org/library/papers/42332075 | PubMed |
| 42,244,822 | The role of esketamine in enhancing postoperative recovery and pain management in laparoscopic surgery: a meta-analysis of randomised controlled trials. | Eur J Anaesthesiol Intensive Care | 2026 | https://conductscience.org/library/papers/42244822 | PubMed |
| 42,138,352 | Drug-induced changes in connectivity to midbrain dopamine cells revealed by rabies monosynaptic tracing. | Elife | 2026 | https://conductscience.org/library/papers/42138352 | PubMed |
| 42,098,542 | Restorative or Disruptive? Effects of Antidepressants on Sleep Architecture in Depression. | CNS Drugs | 2026 | https://conductscience.org/library/papers/42098542 | PubMed |
| 42,066,082 | TrkB/mGluR5 cross-talk underlies a synaptic metaplasticity mechanism of ketamine. | Sci Adv | 2026 | https://conductscience.org/library/papers/42066082 | PubMed |
| 42,030,928 | Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets. | Cell | 2026 | https://conductscience.org/library/papers/42030928 | PubMed |
| 42,011,089 | Ketamine addiction following a single sub-anaesthetic ketamine treatment for acute suicidality in a psychiatrically multimorbid patient: case report. | BJPsych Open | 2026 | https://conductscience.org/library/papers/42011089 | PubMed |
| 41,974,884 | Pleiotropic modulation of the gut-brain-lung axis by ketamine and its enantiomers. | Mol Psychiatry | 2026 | https://conductscience.org/library/papers/41974884 | PubMed |
| 41,968,009 | Serotonergic and glutamatergic mechanisms converge in ketamine's rapid responses. | Trends Neurosci | 2026 | https://conductscience.org/library/papers/41968009 | PubMed |
| 41,929,866 | Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions. | J Anesth Transl Med | 2024 | https://conductscience.org/library/papers/41929866 | PubMed |
| 41,922,775 | A µ-opioid receptor superagonist analgesic with minimal adverse effects. | Nature | 2026 | https://conductscience.org/library/papers/41922775 | PubMed |
| 41,905,327 | Evaluation of optimal dosage combinations of oral midazolam and esketamine for pediatric preoperative sedation: A randomized, double-blind clinical trial. | Clinics (Sao Paulo) | 2026 | https://conductscience.org/library/papers/41905327 | PubMed |
| 41,887,688 | [Esketamine alleviates depression-like behaviors in mice with chronic restraint stress by activating glutamatergic neurons in the medial prefrontal cortex]. | Nan Fang Yi Ke Da Xue Xue Bao | 2026 | https://conductscience.org/library/papers/41887688 | PubMed |
| 41,825,507 | Disruption of psychostimulant-associated memories by single, low dose ketamine in rats. | Neuropharmacology | 2026 | https://conductscience.org/library/papers/41825507 | PubMed |
| 41,648,568 | Negative allosteric modulation of α5-GABAA receptors engages dynamic cortical glutamatergic and GABAergic mechanisms underlying adaptive behavior in mice. | bioRxiv | 2026 | https://conductscience.org/library/papers/41648568 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| OPRK1 | 4,986 | PubTator's text mining | https://conductscience.org/library/genes/4986 | NCBI Gene |
| OPRM1 | 4,988 | PubTator's text mining | https://conductscience.org/library/genes/4988 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33859356
GET https://conductscience.org/api/papers/v1/33859356/references?page=2